New Anti-Clotting Medication Prevents Strokes Without the Usual Bleeding Risk

A global 12,327-patient trial found asundexian lowered the risk of recurrent ischemic stroke and major cardiovascular events.

The benefit was seen after recent non-cardioembolic stroke or high-risk TIA.

Unlike many antithrombotic drugs, it did not increase major bleeding.

The results point to a potential new stroke-prevention option targeting Factor XIa.